(Albany, US) DelveInsight’s “Adeno-Associated Virus Vectors in Gene Therapy Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Adeno-Associated Virus Vectors in Gene Therapy, historical and forecasted epidemiology as well as the Adeno-Associated Virus Vectors in Gene Therapy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some facts of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy report:

• According to DelveInsight’s analysis, the market size for AAV vectors in gene therapy across the 7MM is expected to grow with a significant CAGR by 2032.
• DelveInsight’s analysis reveals that the prevalent cases of selected indications for AAV gene therapies in the 7MM were reported as ~3 million in 2020. 
• Leading AAV vectors in gene therapy companies such as MeiraGTx UK II Ltd, Janssen Research & Development, Adverum Biotechnologies, Inc., Amicus Therapeutics, Audentes Therapeutics, Solid Biosciences, Sio Gene Therapies, Takeda (Shire), Bayer, Pfizer, Freeline Therapeutics, Asklepios BioPharmaceutical, UniQure Biopharma B.V., GenSight Biologics, Regenxbio, Sangamo Therapeutics, Lysogene, Sarepta Therapeutics, Esteve, Abeona Therapeutics, Audentes Therapeutics, Ultragenyx Pharmaceutical, Homology Medicines, BioMarin Pharmaceutical, Spark Therapeutics, Astellas Therapeutics, Actus Therapeutics, GenSight Biologics, 4D Molecular Therapeutics, Roche, Coave Therapeutics, Applied Genetic Technologies Corporation, Vivet Therapeutics, and others are developing novel AAV vectors in gene therapy that can be available in the AAV vectors in gene therapy market in the coming years.
• The promising AAV vectors in gene therapies in the pipeline include AAV-CNGA3, AAV-CNGB3, AGTC-402 (ACHM CNGA3), ACHM B3 (rAAV2tYF-PR1.7-hCNGB3), ADVM-022 (AAV.7m8-aflibercept), AT-GTX-502 (scAAV9.P546.CLN3), AT-GTX-501 (scAAV9.CB.CLN6), scAAV1.tMCK.NTF3, SPK 7001 (AAV2-hCHM), 4D-110, PF-06939926, Delandistrogene moxeparvovec (SRP-9001), scAAV9.U7.ACCA, SGT-001, 4D-310, Isaralgagene civaparvovec, FLT190, AXO-AAV-GM1, AXO-AAV-GM2, DTX401 (AAV8G6PC), Valoctocogene Roxaparvovec (BMN 270), Giroctocogene fitelparvovec (SB-525 or PF-07055480), RG6357 (SPK-8011), RG6358 (SPK-8016), TAK-754 (BAX 888/SHP654), BAY2599023 (DTX201 AAV FVIII), Fidanacogene elaparvovec (SPK-9001/ PF-06838435), Verbrinacogene setparvovec (FLT-180a), AskBio009 (BAX 335, AAV8.sc-TTR-FIXR338Lopt), AMT-130, LUMEVOQ (GS010; lenadogene nolparvovec), SRP-9004 (MYO 102/ scAAVrh74.tMCK.hSGCA), RGX-121, RGX-111, SB-318, ABO-101 (rAAV9.CMV.hNAGLU), LYS-SAF302 (Olenasufligene Relduparvovec), EGT-101 (AAV9-CAG-coh-SGSH), ABO-102 (scAAV9.U1a.hSGSH), AT132, DTX301 (scAAV8OTC), NLX P101 (AAV-GAD), HMI-102, BMN 307, SPK-3006, AT845, ACTUS-101, GS030, AAV-RPGR, AAV-RPE65, 4D-125, ATGC-501 (rAAV2tYF-GRK1-RPGR), CTx-PDE6b, rAAV-hRS1, VTX-801, and others.

 

Get more comprehensive insights into how Adeno-Associated Virus (AAV) Vector-Based Gene Therapy epidemiological trends are impacting current and forecasted Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market @  Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Epidemiology Analysis and Forecast

 

Key Benefits of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Report:

• The report covers the descriptive overview of Adeno-Associated Virus Vectors in Gene Therapy, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Adeno-Associated Virus Vectors in Gene Therapy epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Adeno-Associated Virus Vectors in Gene Therapy are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Adeno-Associated Virus Vectors in Gene Therapy market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Adeno-Associated Virus Vectors in Gene Therapy market

 

To know more about the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market report offerings, click here @ Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Insight

 

The key players in Adeno-Associated Virus Vectors in Gene Therapy market are:

•  Valoctocogene Roxaparvovec (BMN 270): BioMarin Pharmaceutical: Phase III
• PF-06939926: Pfizer: Phase III
• Fidanacogene elaparvovec: Pfizer (initiated by Spark Therapeutics): Phase III
• AMT-061: uniQure/CSL Behring: Phase III
• Timrepigene emparvovec (BIIB111): NightstaRx Ltd, a Biogen Company: Phase III
• Giroctocogene fitelparvovec (SB-525): Pfizer (previously Sangamo Biosciences): Phase III
• BIIB112 (AAV8-RPGR): NightstaRx Ltd, a Biogen Company: Phase II/III
• NLX P101 (AAV-GAD): MeiraGTx: Phase II
• VY-AADC (NBIb-1817/ AAV2-hAADC): Neurocrine Biosciences/ Voyager Therapeutics: Phase II
• SPK-8011: Roche (previously Spark Therapeutics)/Pfizer: Phase I/II
• ST-920: Sangamo Therapeutics: Phase I/II
• FLT190: Freeline Therapeutics: Phase I/II
• SPK-3006 (AAV-sec-GAA): Spark Therapeutics: Phase I/II
• ACTUS-101: Asklepios Biopharmaceutical (Actus Therapeutics): Phase I/II
• AT845: Audentes Therapeutics: Phase I/II
• SRP-9001: Roche/Sarepta Therapeutics: Phase I/IIa
• HORA-PDE6B: Horama S.A.: Phase I/II
• AAV-RPGR (AAV2/5-RPGR): MeiraGTx UK II Ltd: Phase I/II
• RGX-121: RegenxBio: Phase I/II
• SB-913: Sangamo Therapeutics: Phase I/II
• AT-GTX-501 (scAAV9.CB.CLN6): Amicus Therapeutics: Phase I/IIa
• AT-GTX-502 (scAAV9.P546.CLN3): Amicus Therapeutics: Phase I/IIa

 

To know in detail about the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy treatment landscape, click here: Adeno-Associated Virus (AAV) Vector-Based Gene Therapy companies and drugs

 

Adeno-associated virus (AAV) belongs to the genus Dependoparvovirus within the family Parvoviridae. Its life cycle is dependent on the presence of a helper virus, such as AdV, hence its name and taxonomy classification. AAV is found in multiple vertebrate species, including human and non-human primates (NHPs). The current consensus is that AAV does not cause any human diseases. It is composed of an icosahedral protein capsid of ~26 nm in diameter and a single-stranded DNA genome of ~4.7 kb that can either be the plus (sense) or minus (anti-sense) strand.AAV vectors are the leading platform for gene delivery for the treatment of a variety of human diseases.

Recent advances in developing clinically desirable AAV capsids, optimizing genome designs, and harnessing revolutionary biotechnologies have contributed substantially to the growth of the gene therapy field.

Preclinical and clinical successes in AAV-mediated gene replacement, gene silencing, and gene editing have helped AAV gain popularity as the ideal therapeutic vector, with few AAV-based therapeutics gaining regulatory approval in Europe and the United States.

 

Do you want to know how much market share the emerging therapies are going to capture by 2032? Contact: Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Outlook

 

Table of Contents:

1. Key Insights

2. Executive Summary of Adeno-Associated Virus Vectors in Gene Therapy

3. Competitive Intelligence Analysis for Adeno-Associated Virus Vectors in Gene Therapy

4. Adeno-Associated Virus Vectors in Gene Therapy: Market Overview at a Glance

5. Adeno-Associated Virus Vectors in Gene Therapy: Disease Background and Overview

6. Patient Journey

7. Adeno-Associated Virus Vectors in Gene Therapy Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Unmet Needs

10. Key Endpoints of Adeno-Associated Virus Vectors in Gene Therapy Treatment

11. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Marketed Products

12. Emerging Adeno-Associated Virus (AAV) Vector-Based Gene Therapies

13. Adeno-Associated Virus Vectors in Gene Therapy: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Outlook

16. Access and Reimbursement Overview of Adeno-Associated Virus Vectors in Gene Therapy

17. KOL Views

18. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Drivers

19. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

To know more about Emerging Adeno-Associated Virus (AAV) Vector-Based Gene Therapies, click here: Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Treatment Scenario

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services